Segment Information (Tables)

9 Months Ended

Sep. 30, 2024

Segment Reporting [Abstract]

Schedule of Segment Information

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

	Net Sales to External Customers								Operating Earnings
	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended September 30,				Nine Months Ended September 30,
(in millions)	2024		2023		2024		2023		2024		2023		2024		2023
Established Pharmaceutical Products	$	1,406	$	1,368	$	3,926	$	3,844	$	380	$	345	$	962	$	952
Nutritional Products	2,066		2,073		6,284		6,116		312		284		1,062		972
Diagnostic Products	2,412		2,449		6,821		7,454		558		632		1,462		1,720
Medical Devices	4,747		4,249		13,934		12,444		1,513		1,342		4,380		3,805
Total Reportable Segments	10,631		10,139		30,965		29,858		2,763		2,603		7,866		7,449
Other	4		4		11		10
Net sales	$	10,635	$	10,143	$	30,976	$	29,868
Corporate functions and benefit plan costs									(140)		(50)		(286)		(198)
Net interest expense									(51)		(69)		(170)		(182)
Share-based compensation (a)									(117)		(117)		(562)		(530)
Amortization of intangible assets									(470)		(496)		(1,413)		(1,485)
Other, net (b)									(45)		(200)		(452)		(185)
Earnings before taxes									$	1,940	$	1,671	$	4,983	$	4,869

______________________________________

(a)

Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(b)

Other, net for the three and nine months ended September 30, 2024 and 2023 includes charges related to restructurings, the impairment of IPR&D and intangible assets and various investments and integration costs related to business combinations. Other, net for the nine months ended September 30, 2024 includes a loss on the divestiture of a non-core business. Other, net for the three months and nine months ended September 30, 2023 includes costs associated with the acquisition of CSI. Other, net for the nine months ended September 30, 2023 includes income arising from fair value changes in contingent consideration related to previous business combinations.